Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yepeng Luan

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|November 13, 2018
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer TherapyYepeng Luan, Jerry Li, Jean A Bernatchez, et al.
Bioorganic & Medicinal Chemistry Letters|July 10, 2022
Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitorYongliang Li, Yuanpeng Liu, Yiran Chen, et al.
Bioscience Trends|March 15, 2019
Novel HDAC6 selective inhibitors with 4-aminopiperidine-1- carboxamide as the core structure enhanced growth inhibitory activity of bortezomib in MCF-7 cellsChenru Zhao, Jianjun Gao, Li Zhang, et al.
Journal of Natural Products|May 16, 2012
Cytotoxic metabolites from the antarctic psychrophilic fungus Oidiodendron truncatumLiyuan Li, Dehai Li, Yepeng Luan, et al.
Current Protein & Peptide Science|September 8, 2012
The characteristics, functions and inhibitors of three aminopeptidases belonging to the m1 familyYepeng Luan, Chunhua Ma, Yan Wang, et al.
Drug Development Research|October 4, 2019
Novel histone deacetylase inhibitors bearing a 4-piperidin-4-yl-triazole scaffold as antitumor agentsYan Wang, Li Su, Qiang Wang, et al.
Archives of Gerontology and Geriatrics|September 4, 2025
A novel HDAC1-specific inhibitor prevents estrogen deficiency-induced osteoporosis in mice by inhibiting osteoclast functionHang Yuan, Yizhong Bao, Li Li, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2022
Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitorsZiwei Chi, Ying Bai, Jing Li, et al.
Frontiers in Pharmacology|January 23, 2023
Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in ChinaJing Nie, Huina Wu, Lei Sun, et al.
Organic Letters|April 5, 2013
Isolation and photoinduced conversion of 6-epi-stephacidins from Aspergillus taichungensisShengxin Cai, Yepeng Luan, Xianglan Kong, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|November 13, 2018
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer TherapyYepeng Luan, Jerry Li, Jean A Bernatchez, et al.
Bioorganic & Medicinal Chemistry Letters|July 10, 2022
Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitorYongliang Li, Yuanpeng Liu, Yiran Chen, et al.
Bioscience Trends|March 15, 2019
Novel HDAC6 selective inhibitors with 4-aminopiperidine-1- carboxamide as the core structure enhanced growth inhibitory activity of bortezomib in MCF-7 cellsChenru Zhao, Jianjun Gao, Li Zhang, et al.
Journal of Natural Products|May 16, 2012
Cytotoxic metabolites from the antarctic psychrophilic fungus Oidiodendron truncatumLiyuan Li, Dehai Li, Yepeng Luan, et al.
Current Protein & Peptide Science|September 8, 2012
The characteristics, functions and inhibitors of three aminopeptidases belonging to the m1 familyYepeng Luan, Chunhua Ma, Yan Wang, et al.
Drug Development Research|October 4, 2019
Novel histone deacetylase inhibitors bearing a 4-piperidin-4-yl-triazole scaffold as antitumor agentsYan Wang, Li Su, Qiang Wang, et al.
Archives of Gerontology and Geriatrics|September 4, 2025
A novel HDAC1-specific inhibitor prevents estrogen deficiency-induced osteoporosis in mice by inhibiting osteoclast functionHang Yuan, Yizhong Bao, Li Li, et al.
Bioorganic & Medicinal Chemistry Letters|June 1, 2022
Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitorsZiwei Chi, Ying Bai, Jing Li, et al.
Frontiers in Pharmacology|January 23, 2023
Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in ChinaJing Nie, Huina Wu, Lei Sun, et al.
Organic Letters|April 5, 2013
Isolation and photoinduced conversion of 6-epi-stephacidins from Aspergillus taichungensisShengxin Cai, Yepeng Luan, Xianglan Kong, et al.
Pageof 4